E-Newsletter - December 2023
Spotlight on Best-of Publications

Alliance Lauds Researchers MOST Notable MANUSCRIPTS of 2022-2023

“Interrupting Endocrine Therapy to Attempt Pregnancy After Breast Cancer”

N Engl J Med. 2023 May 4;388(18):1645-1656.

Ann Partridge, MD, MPH
Dana-Farber Cancer Institute


“Preoperative Treatment of Locally Advanced Rectal Cancer”
N Engl J Med. 2023 Jul 27;389(4):322-334.

Deborah Schrag, MD
Memorial Sloan Kettering Cancer Center


“BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas”
N Engl J Med. 2023 Jul 13;389(2):118-126.

Priscilla Brastianos, MD*
Massachusetts General Hospital Cancer Center
* Junior Investigator


“Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials”
JAMA Oncol. 2023 Apr 1;9(4):490-499.

Aranzazu Fernandez-Martinez, MD*
 UNC Lineberger Comprehensive Cancer Center
* Junior Investigator



Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
N Engl J Med. 2023 Feb 9;388(6):489-498.
Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain  Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/ Canadian Cancer Trials Group) Randomized Clinical Trial
JAMA Oncol. 2022 Dec 1;8(12):1809-1815.
Palmer JD*, Klamer BG, Ballman KV, Brown PD, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D



The Alliance Publications Committee, in collaboration with the Group Chair’s Office, continues a tradition that began in 2012: to highlight and share our Group’s most notable publications in the fall Group meeting book. This year, four manuscripts were chosen from 51 original Alliance manuscripts published in print or in online-only format between September 1, 2022 and August 31, 2023.

Selection of the most significant manuscripts is based on review by our scientific leadership as well as by a separate review panel. Disease and modality committee chairs and the principal investigators of the Cancer Control Program, Statistics and Data Management Program, and Translational Research Program are asked to nominate up to three manuscripts from their committee or program. Each nominated manuscript must satisfy at least one of the following criteria:

  • Potential to change the standard of care
  • Potential to change the way clinical trials are designed and/or executed
  • Potential to change our understanding of cancer biology

At least one nomination from each committee and program must have a junior investigator (one who has completed training within the previous eight years) as first author, if such a manuscript has been published and meets the qualifications. In nominating a publication, committee chairs and program principal investigators are asked to explain why the published manuscript merited consideration.

The manuscripts considered for selection reflect significant efforts made by Alliance scientific leadership, investigators, operations personnel, and patients who have participated in Alliance trials. Contributions are many, and set the path to better understand cancer biology and its treatment as well as to improve the outcome and quality of life for patients.


Read other articles in this month's e-newsletter: